EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

1-Year Outcomes After Transcatheter Edge-to-Edge Repair in Degenerative MR Stratified by Extent of Cardiac Damage

Abdullah Al-Abcha, D Scott Lim, Jörg Hausleiter, Robert L Smith, Firas Zahr, Scott Chadderdon, Raj Makkar, Moody M Makar, Ralph Stephan von Bardeleben, Tobias Friedrich Ruf, Theresa Gößler, Robert M Kipperman und 12 weitere

JACC: Cardiovascular Interventions · 2025-11 · 18 (21) · 2596-2611

DOI: 10.1016/j.jcin.2025.08.039 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2025-11. Verfasst von Abdullah Al-Abcha und 23 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Mitral Valve Insufficiency, Heart Valve Prosthesis Implantation, Cardiac Catheterization, Mitral Valve. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The impact of extramitral cardiac damage (EMCD) in patients undergoing mitral valve transcatheter edge-to-edge repair (M-TEER) for degenerative mitral regurgitation (DMR) is unknown. OBJECTIVES: The aim of this study was to understand M-TEER outcomes stratified by the extent of EMCD. METHODS: One-year outcomes from the randomized CLASP IID (Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial) trial (NCT03706833) in prohibitive surgical risk patients with 3+ or 4+ DMR were analyzed by baseline EMCD stages (stage 0, no EMCD; stage 1, left ventricular remodeling; stage 2, left atrial remodeling; stage 3, pulmonary hypertension and/or tricuspid regurgitation; stage 4, right ventricular dysfunction). RESULTS: The analysis included 211 patients: 53.1% in stages 0, 1, and 2 (n = 112), 13.3% in stage 3 (n = 28), and 33.6% in stage 4 (n = 71). Stages 0, 1, and 2 were combined because there were few patients in stage 0 (n = 3) and stage 1 (n = 1). At baseline, patients with more advanced cardiac damage had more comorbidities, lower functional and quality-of-life measures, and greater mitral regurgitation severity. One-year rates of clinical events among all stages were comparable for major adverse events (P = 0.343) and all-cause mortality (P = 0.644) and significantly different for heart failure hospitalization (P = 0.012). Patients in all stages achieved comparable echocardiographic and quality-of-life improvements at 1 year, including mitral regurgitation ≤1+ (P = 0.474), left ventricular diastolic (P = 0.619) and systolic (P = 0.676) volumes, and Kansas City Cardiomyopathy Questionnaire score (P = 0.335), with significant improvements from baseline (P < 0.05 vs baseline for all). CONCLUSIONS: Results from the CLASP IID trial demonstrate benefit of M-TEER in DMR patients across all EMCD stages, including stage 4, with low major adverse events and all-cause mortality and comparable significant improvements in echocardiographic and quality-of-life outcomes at 1 year.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mitral Valve InsufficiencyHeart Valve Prosthesis ImplantationCardiac CatheterizationMitral ValveHumansMaleFemaleTreatment OutcomeTime FactorsAgedRisk FactorsRecovery of FunctionVentricular RemodelingSeverity of Illness IndexVentricular Function, LeftAged, 80 and overAtrial RemodelingQuality of LifeHeart Valve ProsthesisVentricular Function, RightAtrial Function, LeftRisk Assessment

Stichwörter der Autor:innen

M-TEERPASCAL systemextramitral cardiac damagemitral valve transcatheter edge-to-edge repairpulmonary hypertensionright ventricular dysfunction

Autor:innen und Institutionen

  • Mayo Clinic, Rochester, Minnesota, USA.
  • University of Virginia Health System Hospital, Charlottesville, Virginia, USA.
  • Klinikum der Universität München, Munich, Germany.
  • Baylor Scott and White: The Heart Hospital, Plano, Texas, USA.
  • Oregon Health & Science University, Portland, Oregon, USA.
  • Cedars-Sinai Medical Center, Los Angeles, California, USA.

Zitieren

APA

Al-Abcha, A., Lim, D. S., Hausleiter, J., Smith, R. L., Zahr, F., Chadderdon, S., Makkar, R., Makar, M. M., von Bardeleben, R. S., Ruf, T. F., Gößler, T., Kipperman, R. M., Rassi, A. N., Ku, I. A., Nabauer, M., Szerlip, M., Wang, Z., Goldman, S., Hawthorne, K. M., …, & CLASP IID Pivotal Trial Investigators (2025). 1-Year Outcomes After Transcatheter Edge-to-Edge Repair in Degenerative MR Stratified by Extent of Cardiac Damage. JACC: Cardiovascular Interventions, 18(21), 2596-2611. https://doi.org/10.1016/j.jcin.2025.08.039

Vancouver

Al-Abcha A, Lim DS, Hausleiter J, Smith RL, Zahr F, Chadderdon S, et al. 1-Year Outcomes After Transcatheter Edge-to-Edge Repair in Degenerative MR Stratified by Extent of Cardiac Damage. JACC: Cardiovascular Interventions. 2025;18(21):2596-2611. doi:10.1016/j.jcin.2025.08.039

BibTeX
@article{AlAbcha2025,
  author = {Al-Abcha, Abdullah and Lim, D Scott and Hausleiter, Jörg and Smith, Robert L and Zahr, Firas and Chadderdon, Scott and Makkar, Raj and Makar, Moody M and von Bardeleben, Ralph Stephan and Ruf, Tobias Friedrich and Gößler, Theresa and Kipperman, Robert M and Rassi, Andrew N and Ku, Ivy A and Nabauer, Michael and Szerlip, Molly and Wang, Zuyue and Goldman, Scott and Hawthorne, Katie M and Koulogiannis, Konstantinos and Marcoff, Leo and Gillam, Linda D and Guerrero, Mayra E and CLASP IID Pivotal Trial Investigators, CLASP IID Pivotal Trial Investigators},
  title = {1-Year Outcomes After Transcatheter Edge-to-Edge Repair in Degenerative MR Stratified by Extent of Cardiac Damage},
  journal = {JACC: Cardiovascular Interventions},
  year = {2025},
  volume = {18},
  number = {21},
  pages = {2596--2611},
  doi = {10.1016/j.jcin.2025.08.039}
}
Kostenlos starten →